Browse By Viral Diseases

This page shows data for COVID-19 disease.
Total Entries Retrieved: 214
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10001 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. 2020 USA 18 years and above 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine US FDA NA USA, Canada, UK, Netherlands, Denmark, Germany, Switzerland mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran NA NCT04969250 https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine NA
10002 CoronaVac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Sinovac Biotech Ltd. 2021 China 18 - 59 years 2 doses 28 days apart Intramuscular NA Antigenic strain of H1N1, H3N2, BV and BY NA NA NA NA PiCoVacc, Inactivated SARS-CoV-2 vaccine (Vero cell) NA NCT04801888 https://clinicaltrials.gov/show/NCT04801888 https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/4_sage29apr2021_sinovac.pdf
10003 Inactivated SARS-CoV-2 vaccine (Vero cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Hubei Provincial Center for Disease Control and Prevention 2020 China NA NA Intramuscular NA NA NA NA NA NA NA NA NA http://www.chictr.org.cn/showproj.aspx?proj=126385 NA
10004 Inactivated SARS-CoV-2 vaccine (Vero cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Shanghai Municipal Center for Disease Control and Prevention 2021 China NA NA Intramuscular NA NA NA NA NA NA NA NA NA http://www.chictr.org.cn/showproj.aspx?proj=126277 NA
10005 KconecaVac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Shenzhen Kangtai Biological Products Co. Ltd 2021 China 18 years and above 2 doses 28 days apart Intramuscular NA NA NA China FDA NA NA NA NA NCT04852705 https://clinicaltrials.gov/show/NCT04852705 https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai/kangtai-biologicals-covid-19-vaccine-gets-emergency-use-approval-in-china-idUSKBN2CV1F6
10006 Inactivated SARS-CoV-2 vaccine (Vero cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Shanghai Oriental Hospital 2021 China NA NA Intramuscular NA NA NA NA NA NA NA NA NA http://www.chictr.org.cn/showproj.aspx?proj=122756 NA
10007 Abdala COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Center for Genetic Engineering and Biotechnology 2021 Cuba 19 - 80 years NA Intramuscular Aluminum (aluminium hydroxide) NA NA Cuba Drug Regulator NA Cuba, Venezuela CIGB-66 NA NA https://rpcec.sld.cu/en/trials/RPCEC00000363-En https://rpcec.sld.cu/en/trials/RPCEC00000359-En
10008 PiCoVacc COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Live-attenuated Approved Sinovac Biotech Ltd. 2020 China 18 - 59 years 2 doses 14 or 28 days apart Intramuscular Aluminum (alum) NA NA WHO NA Brazil, Indonesia, Turkey CoronaVac 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202686/
10009 Sinopharm Vaccine (Vero cell inactivated) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Live-attenuated Approved Sinopharm 2020 China NA 2 doses 14 or 21 days apart Intramuscular Aluminum (alum) NA NA WHO NA Jordan, Bahrain, Morocco, UAE NA 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://covid19.health.gov.mv/wp-content/uploads/2021/10/SINOPHARM-INFORMATION-SHEET_Final-Revised-09th-June.pdf
10010 BBIBP-CorV (Vero cell) (Covilo) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Live-attenuated Approved China National Biotec Group Company Limited 2021 China 18 years and above 2 doses 14 or 28 days apart Intramuscular Aluminum NA NA WHO Beijing Institute of Biotechnology UAE, Jordan, Egypt, Bahrain, Argentina BBIBP-CorV, COVILO 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://www.precisionvaccinations.com/vaccines/sinopharm-covid-19-vaccine-bbibp-corv
10011 Zifivax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Anhui Zhifei Longcom Biologic Pharmacy Co. Ltd. 2020 China NA 2 doses 2 to 3 days apart Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein NA China FDA Institute of Microbiology of the Chinese Academy of Sciences China, Uzbekistan, Indonesia, Pakistan, Ecuador RBD-Dimer, ZF2001 33816047 NCT04646590 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT05091411
10012 SARS-CoV-2 Vaccine (VeroCell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Sinopharm, Beijing Institute of Biological Products 2020 China NA 2 doses 21 days apart Intramuscular NA NA NA WHO NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://cdn.who.int/media/docs/default-source/immunization/covid-19/16-june-22080-sinopharm-vaccine-explainer-update.pdf?sfvrsn=ad833095_1&download=true
10013 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India 2020 England NA 2 doses 28 days apart Intramuscular NA SARS-CoV-2 Spike gene to the replication defective chimpanzee adenovirus ChAdOx1 NA US FDA NA UK, USA, Japan, South Africa AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637436/
10014 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved AstraZeneca plc, University of Oxford, Serum Institute of India 2020 England NA NA Intramuscular NA NA mRNA based vaccine European Inclusive Vaccines Alliance NA UK, USA, Brazil, South Africa AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria 33324769 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729279/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637436/
10015 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India NA NA NA 2 doses 4 weeks apart Intramuscular NA NA NA NA NA Argentina, India, Morocco, Britain, Mexico, El Salvador, Dominican Republic AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://vk.ovg.ox.ac.uk/vk/covid-19-vaccines https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know
10016 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India NA NA NA 2 doses 28 days apart Intramuscular NA NA NA US FDA NA NA AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10017 Convidecia COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved CanSino Biologics Inc. 2020 China 6 - 59 years 2 doses Intramuscular NA Spike protein of SARS-CoV-2 virus Viral vector vaccine using a replication-defective form of the human adenovirus Ad5 NMPA Jiangsu Province Centers for Disease Control and Prevention, Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China China, Chile, Hungary, Malaysia, Mexico, Pakistan Ad5-nCoV 32328406 NCT04916886 https://pubmed.ncbi.nlm.nih.gov/32328406/ https://extranet.who.int/pqweb/vaccines/convidecia
10018 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved Johnson & Johnson 2021 USA 18 - 65 years Single dose Intramuscular NA Spike protein of SARS-CoV-2 virus NA US FDA, WHO NA Netherlands, USA, Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, Ukraine, Belgium, Colombia, France, Germany, Philippines, Spain, UK, Europe Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine 32328406 NCT04927936 https://pubmed.ncbi.nlm.nih.gov/32328406/ https://www.ema.europa.eu/en/documents/product-information/jcovden-previously-covid-19-vaccine-janssen-epar-product-information_en.pdf
10019 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved Janssen Pharmaceutical NA NA NA 2 doses 56 days apart Intramuscular NA NA NA US FDA NA NA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://www.fda.gov/media/153439/download
10020 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved Janssen Pharmaceutical 2020 Russia NA 2 doses 21 days apart Intramuscular NA Heterologous formulation consisting of two human adenovirus vectors, Ad26 and Ad5, both carrying the SARS-CoV-2 spike protein NA US FDA Health Ministry of the Russian Federation NA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ NA
10021 Gam-COVID-Vac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved Gamaleya Research Institute of Epidemiology and Microbiology NA Russia NA 2 doses 3 weeks apart Intramuscular NA NA NA US FDA Health Ministry of the Russian Federation Russia, Bolivia, Argentina, Algeria, Serbia, Belarus Sputnik-V NA NA https://www.precisionvaccinations.com/vaccines/sputnik-v-vaccine NA
10022 Gam-COVID-Vac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved Gamaleya Research Institute of Epidemiology and Microbiology NA Russia NA NA Intramuscular NA NA NA EMA NA NA Sputnik-V 33324769 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729279/ NA
10023 Gam-COVID-Vac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved Gamaleya Research Institute of Epidemiology and Microbiology NA Russia NA 2 doses 21 days apart Intramuscular NA rAd26-S, rAd5-S NA US FDA Health Ministry of the Russian Federation NA Sputnik-V 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10024 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved BioNTech SE, Pfizer Inc. NA Germany 18 - 85 years NA Intramuscular NA SARS-CoV-2 spike protein mRNA encapsulated in a lipid nanoparticle NA US FDA NA USA, Argentina, Brazil, Germany, South Africa, Turkey BNT162b2, COVID-19 mRNA vaccine, Tozinameran 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf
10025 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved BioNTech SE, Pfizer Inc. 2021 Germany, USA NA NA Intramuscular NA NA mRNA based vaccine US FDA NA NA BNT162b2, COVID-19 mRNA vaccine 33610448 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881713/ NA
10026 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved BioNTech SE, Pfizer Inc. NA USA 12 years and above 2 doses 3 weeks apart Intramuscular NA Trimerized SARS-CoV-2 receptor-binding domain from spike protein mRNA based vaccine US FDA NA Argentina, Canada, Chile, Costa Rica, Ecuador, Jordan, Kuwait, Mexico, Panama, Singapore, Bahrain, Saudi Arabia, Switzerland, European Union BNT162b2, COVID-19 mRNA vaccine, Tozinameran 33826439 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040490// https://www.comirnaty.com/
10027 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. 2020 USA NA 2 doses Intramuscular NA SARS-CoV-2 spike protein mRNA encapsulated in a lipid nanoparticle NA US FDA NA NA mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html
10028 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. NA NA NA 2 doses 28 days apart Intramuscular NA NA NA US FDA National Institute of Allergy and Infectious Diseases NA mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10029 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. NA NA NA 2 doses 4 weeks apart Intramuscular NA NA NA US FDA NA USA, Canada, Israel, European Union mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran 33826439 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040490/ NA
10030 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Novavax Inc. NA UK NA 2 doses Intramuscular Matrix-M Spike protein of SARS-CoV-2 virus NA US FDA NA USA, Mexico TAK-019, SARS-CoV-2 rS, NVX-CoV2373 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://clinicaltrials.gov/ct2/show/NCT05249816
10031 Covaxin COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Bharat Biotech International Limited 2021 India 18 years and above NA Intramuscular NA NA NA DCGI, WHO Indian Council of Medical Research, Iqvia Pty Ltd NA NA NA NCT04641481 https://clinicaltrials.gov/ct2/show/NCT04641481 https://www.clinicaltrialsarena.com/projects/covaxin-bbv152-for-the-treatment-of-covid-19/
10032 Covifenz COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Approved Medicago Inc 2021 Canada 18 years and above 2 doses 21 days apart Intramuscular AS03 NA NA Health Canada NA NA CoVLP NA NCT05040789 https://clinicaltrials.gov/ct2/show/NCT05040789 https://www.precisionvaccinations.com/vaccines/covifenz-covlp-covid-19-vaccine
10033 EpiVacCorona COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved FBRI State Research Center of Virology and Biotechnology 2020 Russia 18 years and above 2 doses 21 days apart Intramuscular Aluminum (aluminium hydroxide) SARS CoV-2 peptide antigens NA Russian Federation FBRI State Research Center of Virology and Biotechnology NA EpiVacCorona-N, Aurora-CoV 33816047 NCT04780035 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html
10034 MVC-COV1901 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Medigen Vaccine Biologics, Dynavax 2021 Taiwan 12 years and above 2 doses 28 days apart Intramuscular CpG 1018, aluminium hydroxide S-2P protein NA Taiwan FDA National Institute of Allergy and Infectious Diseases Thailand, Taiwan, Paraguay NA 33816047 NCT05198596 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://www.precisionvaccinations.com/vaccines/medigen-covid-19-vaccine
10035 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved BioNTech SE, Pfizer Inc. 2020 Germany 18 - 55 years 2 doses 21 days apart Intramuscular NA Trimerized SARS-CoV-2 receptor-binding domain from spike protein mRNA based vaccine US FDA NA Argentina, Brazil, Germany, South Africa, Turkey, USA BNT162b2, COVID-19 mRNA vaccine 33402220 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ NA
10036 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. 2020 USA 18 - 55 years 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine US FDA NA NA mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran 33402220 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ NA
10037 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Approved Janssen Pharmaceutical NA NA 18 years and above Single dose Intramuscular NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine 33402220 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ NA
10038 Gam-COVID-Vac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Approved Gamaleya Research Institute of Epidemiology and Microbiology 2020 Russia 18 - 60 years NA Intramuscular NA Spike protein of SARS-CoV-2 virus NA US FDA Health Ministry of the Russian Federation NA Sputnik-V 33402220 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ NA
10039 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Novavax Inc. 2021 USA 12 years and above 2 doses 21 days apart Intramuscular Matrix-M1 Spike protein of SARS-CoV-2 virus NA WHO NA USA, Mexico, Puerto Rico, UK NVX-CoV2373 33402220 NCT04611802 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ https://www.drugs.com/history/novavax-covid-19-vaccine.html
10040 EpiVacCorona COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved FBRI State Research Center of Virology and Biotechnology 2021 Russia 18 - 60 years 2 doses 21 or 28 days apart Intramuscular Aluminum (aluminium hydroxide) SARS-CoV-2 protein NA Russian Federation FBRI State Research Center of Virology and Biotechnology Cambodia, Russia, Turkmenistan EpiVacCorona-N, Aurora-CoV 33402220 NCT04780035 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ https://clinicaltrials.gov/ct2/show/NCT04780035
10041 COVILO (BBIBP-CorV) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved China National Biotec Group Company Limited 2021 China 3 years and above 2 doses 21 days apart Intramuscular Aluminum (aluminium hydroxide) Inactivated SARS-CoV-2 virus Inactivated SARS-CoV-2 vaccine (Vero cell) is prepared by inoculating African green monkey kidney cells (Vero cell) with the SARS-CoV-2 HB02 strain WHO, Caribbean Regulatory System Emergency Use Recommendation Beijing Institute of Biotechnology China, Bahrain, Egypt, Jordan, UAE, Hungary, Pakistan NA 33402220 NCT04863638 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ https://www.carpha.org/Portals/0/Documents/COVID-19%20Vaccine%20Updates/CARPHA%20COVID-19%20Vaccine%20Update%20047%20December%206%202021.pdf
10042 PiCoVacc COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Sinovac Biotech Ltd. 2021 Brazil 18 - 59 years 2 doses 28 days apart Intramuscular NA Inactivated SARS-CoV-2 virus NA WHO, Caribbean Regulatory System Emergency Use Recommendation, Africa Regulatory Taskforce Endorsed NA NA CoronaVac 33402220 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
10043 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved BioNTech SE, Pfizer Inc. 2021 Germany, USA NA NA Intramuscular NA NA mRNA based vaccine US FDA NA NA BNT162b2, COVID-19 mRNA vaccine NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://www.who.int/publications/m/item/comirnaty-covid-19-mrna-vaccine#:~:text=Pfizer%2DBioNTech%20COVID%2D19%20Vaccine%2C%20COMIRNATY%C2%AE%20(Tozinameran),-COVID%2D19%20Vaccine&text=This%20vaccine%20resource%20provides%20key,disease%20(COVID%2D19).
10044 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India 2020 UK NA NA Intramuscular NA NA Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 EMA NA NA AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf NA
10045 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India NA India NA NA Intramuscular NA NA Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 DCGI NA NA AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf NA
10046 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved Janssen Vaccines & Prevention B.V. NA Leiden, Netherlands NA NA Intramuscular NA NA Recombinant replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding Spike protein antigen of the SARS-CoV-2 EMA NA NA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf NA
10047 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Approved Moderna Inc. 2020 USA NA NA Intramuscular NA NA mRNA based vaccine EMA NA NA mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf NA
10048 COVILO (BBIBP-CorV) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Sinopharm, Beijing Institute of Biological Products NA China NA NA Intramuscular NA Inactivated SARS-CoV-2 virus Produced in vero cells NMPA, WHO NA NA Inactivated SARS-CoV-2 vaccine (Vero cell) NA NA https://cdn.who.int/media/docs/default-source/immunization/covid-19/16-june-22080-sinopharm-vaccine-explainer-update.pdf?sfvrsn=ad833095_1&download=true https://cdn.who.int/media/docs/default-source/immunization/covid-19/16-june-22080-sinopharm-vaccine-explainer-update.pdf?sfvrsn=ad833095_1&download=true
10049 CoronaVac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Sinovac Biotech Ltd. NA China 18 years and above NA Intramuscular Aluminum (aluminium hydroxide) Inactivated SARS-CoV-2 virus Vero cells NMPA, WHO NA NA Inactivated SARS-CoV-2 Vaccine (Vero Cell) (lnCoV),CoronaVac NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://clinicaltrials.gov/ct2/show/NCT05107557
10050 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India NA UK NA NA Intramuscular NA NA Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 Japan MHLW NA NA AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://www.who.int/publications/m/item/chadox1-s-recombinant-covid-19-vaccine
10051 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India NA UK NA NA Intramuscular NA NA Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 Australia TGA NA NA AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://www.who.int/publications/m/item/chadox1-s-recombinant-covid-19-vaccine
10052 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Subunit vaccine Approved Novavax Inc. 2020 USA NA NA Intramuscular NA NA Recombinant nanoparticle prefusion spike protein formulated with Matrix adjuvant EMA, WHO NA NA TAK-019, SARS-CoV-2 rS, NVX-CoV2373 NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://www.who.int/news-room/feature-stories/detail/the-novavax-vaccine-against-covid-19-what-you-need-to-know
10053 Covaxin COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Bharat Biotech International Limited NA India NA NA Intramuscular NA NA Produced in vero cells DCGI NA NA NA NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://www.precisionvaccinations.com/vaccines/covaxin-covid-19-vaccine
10054 EpiVacCorona COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Vector State Research Centre of Viralogy and Biotechnology NA Russia NA NA Intramuscular NA NA NA Russian Federation NA Russia, Cambodia EpiVacCorona-N, Aurora-CoV NA NCT04780035 https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html https://www.precisionvaccinations.com/vaccines/epivaccorona-vaccine#:~:text=EpiVacCorona%20(Aurora%2DCoV)%20is,19%20and%20promotes%20immunity%20development.
10055 Zifivax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Anhui Zhifei Longcom Biologic Pharmacy Co. Ltd. NA China NA NA Intramuscular NA NA Recombinant UAE NA NA Recombinant Novel Coronavirus Vaccine CHO Cell) NA NCT04550351 https://clinicaltrials.gov/ct2/show/NCT04550351 https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04646590
10056 Pasteur COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved BioCubaFarma 2021 Cuba NA NA Intramuscular NA Spike protein of SARS-CoV-2 virus NA CECMED NA NA FINLAY-FR-2, Pasteurcovac, Pasto Covac, Soberana 02 NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://rpcec.sld.cu/trials/RPCEC00000354-En
10057 Corbevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Subunit vaccine Approved Biological E Limited 2021 India 18 - 65 years 2 doses 28 days apart Intramuscular NA NA NA NA NA NA BECOV2A NA NA http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329&EncHid=&userName=covid-19%20vaccine NA
10058 TAK-019 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Approved Takeda Pharmaceutical Company Limited 2021 USA 20 years and above 2 doses 21 days apart Intramuscular NA NA NA US FDA, Japan MHLW NA Indonesia, Philippines, Japan NA NA NCT05299359 https://clinicaltrials.gov/ct2/show/NCT05299359 NA
10059 VLA2001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Valneva 2021 Austria 18 years and above 2 doses 28 days apart Intramuscular CpG 1018, aluminium hydroxide NA NA EMA NA NA NA NA NCT04864561 https://clinicaltrials.gov/show/NCT04864561 https://valneva.com/press-release/valneva-receives-marketing-authorization-in-europe-for-inactivated-whole-virus-covid-19-vaccine-vla2001/#:~:text=VLA2001%20is%20the%20only%20whole,to%2050%20years%20of%20age.
10060 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved Janssen Pharmaceutical 2020 USA 18 years and above NA Intramuscular NA NA NA US FDA, WHO, Africa Regulatory Taskforce Endorsed, Caribbean Regulatory System Emergency Use Recommendation NA Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, Ukraine, USA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine NA NCT04436276 https://clinicaltrials.gov/show/NCT04436276 NA
10061 Razi Cov Pars COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Subunit vaccine Approved Razi Vaccine, Serum Research Institute 2021 Iran 18 years and above 2 doses 21 days apart Intramuscular NA NA NA Iran FDA NA NA NA NA NA https://www.irct.ir/trial/58143 NA
10062 SpikoGen COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Subunit vaccine Approved Vaxine, CinnaGen 2021 Iran 18 years and above 2 doses 21 days apart Intramuscular Advax-SM Spike protein of SARS-CoV-2 virus NA Iran FDA NA NA NA NA NCT05005559 https://covid19.trackvaccines.org/vaccines/8/ NA
10063 COVIran Barekat COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Shifa Pharmed Industrial Co. 2021 Iran 18 - 75 years 2 doses 28 days apart Intramuscular NA NA NA Iran FDA NA NA NA NA NA https://en.irct.ir/trial/54881 https://www.rferl.org/a/iran-domestic-covid-vaccine-coviran-barekat/31307467.html
10064 FINLAY-FR-2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Subunit vaccine Approved Instituto Finlay de Vacunas 2021 Cuba 19 years and above NA Intramuscular NA NA NA CECMED NA Iran, Cuba Soberana 02 NA NA https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergencia-vacunas-cubanas-soberana-02-soberana-plus NA
10065 ZyCoV-D COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Approved Zydus Candila Healthcare Limited 2021 India 12 years and above NA Intradermal NA SARS CoV-2 envelope protein NA DCGI NA India NA NA NA https://pib.gov.in/PressReleasePage.aspx?PRID=1747669#:~:text=Zydus%20Cadila%20has%20received%20approval,adults%2012%20years%20and%20above. NA
10066 FAKHRAVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Erciyes University, Organization of Defensive Innovation and Research 2021 Iran 18 - 70 years NA Intramuscular NA SARS-CoV-2 NA Iran FDA Organization of Defensive Innovation and Research NA MIVAC, TURKOVAC NA NA https://en.irct.ir/trial/56027 https://www.tehrantimes.com/news/466570/Two-homegrown-vaccines-receive-emergency-use-license
10067 KCONVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Approved Shenzhen Kangtai Biological Products Co. Ltd 2021 China 18 years and above 2 doses 28 days apart Intramuscular NA NA NA China FDA Beijing Minhai Biotechnology Co. China, Indonesia NA NA NCT05204589 https://clinicaltrials.gov/ct2/show/NCT05204589 https://www.reuters.com/article/us-health-coronavirus-vaccine-kangtai/kangtai-biologicals-covid-19-vaccine-gets-emergency-use-approval-in-china-idUSKBN2CV1F6
10146 KCONVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 1 Beijing Minhai Biotechnology Co. Ltd. 2021 China 18 years and above NA Intramuscular NA NA NA NA NA NA NA NA NCT04758273 https://clinicaltrials.gov/show/NCT04758273 https://covid-19pharmacovigilance.paho.org/sinopharmbibp
10147 CoV2-OGEN1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 US Specialty Formulations, VaxForm LLC. 2021 New Zealand 18 - 56 years 2 doses 14 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04893512 https://clinicaltrials.gov/show/NCT04893512 NA
10148 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Universitätsklinikum Hamburg-Eppendorf 2021 Germany 18 - 55 years 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Ludwig-Maximilians, University of Munich NA NA NA NCT04569383 https://clinicaltrials.gov/show/NCT04569383 NA
10149 OSE13E COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 OSE Immunotherapeutics 2021 Belgium 18 - 45 years 2 doses 21 days apart Subcutaneous NA 11 different proteins of SARS-CoV-2 virus NA NA NA NA CoVepiT NA NCT04885361 https://clinicaltrials.gov/show/NCT04885361 NA
10150 Covigenix VAX-001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Entos Pharmaceuticals Inc. 2020 Canada 18 - 85 years 2 doses 14 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus Fusogenix PLV NA Canadian Institutes of Health Research NA NA NA NCT04591184 https://clinicaltrials.gov/ct2/show/NCT04591184 https://clinicaltrials.gov/ct2/history/NCT04591184
10151 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Novavax Inc. NA NA NA NA Intramuscular Matrix-M1 Spike protein of SARS-CoV-2 virus NA NA NA NA TAK-019, SARS-CoV-2 rS 32585611 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301105/ https://clinicaltrials.gov/ct2/show/NCT04368988
10152 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation NA NA 18 - 59 years NA Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 32585611 NCT04334980 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301105/ NA
10153 AdCOVID COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 Altimmune Inc. NA USA 18 - 55 years NA Intranasal NA NA NA NA NA NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10154 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 University Medical Center Hamburg-Eppendorf NA Germany 18 - 55 years NA Intramuscular NA NA NA NA NA NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10155 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 Ludwig-Maximilians, University of Munich NA NA NA 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10156 VXA-CoV2-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Vaxart 2021 USA 18 - 55 years 2 doses 28 days apart Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33937326 NCT04563702 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10157 VXA-CoV2-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Vaxart 2021 USA 18 - 54 years 2 doses 28 days apart Oral NA NA Ad5 adjuvanted Oral Vaccine platform NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10158 GRAd-COV2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 ReiThera Srl 2021 Italy 18 - 85 years NA Intramuscular NA NA NA NA NA NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10159 KCONVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 1 Shenzhen Kangtai Biological Products Co. Ltd NA NA NA 1- 3 doses depending on volume and age Intramuscular NA NA NA NA NA NA Inactivated SARS-CoV-2 vaccine (Vero cell) 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10160 CVXGA1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 CyanVac LLC 2021 USA 18 - 75 years Single dose Intranasal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA PIV5-SARS CoV-2 vaccine NA NCT04954287 https://clinicaltrials.gov/ct2/show/NCT04954287 NA
10161 COVID-19 rNDV vector vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Laboratorio Avi-Mex 2021 Mexico 18 - 55 years 2 doses 21 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04871737 https://clinicaltrials.gov/ct2/show/study/NCT04871737 NA
10162 COVI-VAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Live-attenuated Phase 1 Codagenix Inc. 2021 UK 18 - 30 years 2 doses 28 days apart Intranasal NA SARS CoV 2 whole virus NA NA Serum Institute of India NA CDX-005 33816047 NCT04619628 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10163 BriLife COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Israel Institute for Biological Research NA NA NA Single dose Intramuscular NA NA NA NA NA NA rVSV-SARS-CoV-2-S Vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10164 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation NA NA NA Single dose Oral NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10165 Koçak-19 Inaktif Covid-19 Vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 1 Kocak Farma 2021 Turkey 18 - 55 years 2 doses 21 days apart Intramuscular NA SARS CoV 2 whole virus NA NA NA NA NA NA NCT04838080 https://clinicaltrials.gov/ct2/show/NCT04838080 NA
10166 ChulaCov19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Chulalongkorn University NA NA NA 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10167 CORVax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Providence Health & Services NA NA NA 2 doses 14 days apart Intradermal NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10168 Covigenix VAX-001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Entos Pharmaceuticals Inc. 2021 Canada NA 2 doses 14 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10169 AdimrSC-2f COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Adimmune Corporation 2021 Taiwan 20 - 60 years NA Intramuscular Aluminum Recombinant receptor binding domain of SARS-CoV-2 spike protein NA NA NA NA NA 33816047 NCT04522089 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT05104489
10170 Shingrix COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 University of Oklahoma  NA NA NA 2 doses 60 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10171 SARS-CoV-2 VLP vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 1 The Scientific and Technological Research Council of Turkey 2021 Turkey 18 - 45 years 2 doses 21 days apart Subcutaneous Alumium hydroxide, CpG ODN Inactivated SARS-CoV-2 virus NA NA NA NA NA NA NCT04866069 https://clinicaltrials.gov/ct2/show/study/NCT04866069 NA
10172 COVID-19 aAPC vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Shenzhen Geno-Immune Medical Institute 2021 China 6 months - 80 years 3 doses on day 0, 14 and 28 Subcutaneous NA NA The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune-modulatory genes and the viral minigenes to the artificial antigen-presenting cells NA NA NA NA 33816047 NCT04299724 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10173 SARS-CoV-2 mRNA vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Shulan (Hangzhou) Hospital NA NA NA 2 doses 14 days apart Intramuscular NA NA NA NA Guangxi CDC NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10174 LNP-nCoVsaRNA COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Imperial College London 2021 UK 18 - 75 years 2 doses Intramuscular NA Self-amplifying RNA SARS-CoV-2 lipid nanoparticle NA NA NA NA COVAC1 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10175 MV-014-212 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Live-attenuated Phase 1 Meissa Vaccines Inc. 2021 USA 18 - 69 years 2 doses 35 days apart Intranasal NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04798001 https://clinicaltrials.gov/ct2/show/NCT04798001?term=covid-19+vaccine&draw=2 NA
10176 Noora vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Bagheiat-allah University of Medical Sciences 2021 Iran 18 - 50 years 3 doses on day 0, 21 and 35 Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA AmitisGen NA NA https://en.irct.ir/trial/56987 NA
10177 COVAX-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Vaxine, Medytox NA NA NA Single dose Intramuscular NA NA NA NA NA NA COVID-19 vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10178 SpFN COVID-19 Vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 US Army Medical Research and Development Command 2021 USA 18 - 55 years 3 doses on day 1, 29 and 181 Intramuscular Army Liposomal Formulation QS21 Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA NA NCT04784767 https://clinicaltrials.gov/show/NCT04784767 NA
10179 ChAdV68-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Gritstone Oncology 2021 USA 18 years and above 2 doses 28 days apart Intramuscular Aluminum (alum) SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT04760743 https://clinicaltrials.gov/ct2/show/NCT04760743 NA
10180 iNCOVACC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 Bharat Biotech International Limited 2021 India 18 - 60 years 2 doses 28 days apart Intranasal NA Spike protein of SARS-CoV-2 virus NA NA NA NA BBV154 NA NA http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=51327 NA
10181 PTX-COVID19-B COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Providence Therapeutics Holdings Inc. 2021 Canada 18 - 64 years 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04765436 https://clinicaltrials.gov/show/NCT04765436 NA
10182 ReCOV COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 Jiangsu Rec-Biotechnology Co. Ltd. 2021 New Zealand 18 - 60 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04818801 https://clinicaltrials.gov/ct2/show/NCT04818801 NA
10183 NBP2001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 SK Bioscience Co. Ltd. 2021 South Korea 19 - 55 years 2 doses 28 days apart Intramuscular MF59 SARS CoV-2 Receptor Binding domain NA NA NA NA NA NA NCT04760743 https://clinicaltrials.gov/show/NCT04760743 NA
10184 SC-Ad6-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Tetherex Pharmaceuticals Corporation 2021 Australia 18 - 55 years Single or multiple-dose Intramuscular, Intranasal NA NA NA NA NA NA NA NA NCT04839042 https://clinicaltrials.gov/ct2/show/NCT04839042 NA
10185 Turkovac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 1 Health Institutes of Turkey 2020 Turkey 18 - 55 years 2 doses 21 days apart Intramuscular NA NA NA NA NA NA ERUCOV-VAC NA NCT04691947 https://clinicaltrials.gov/show/NCT04691947 NA
10186 bacTRL-Spike vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Symvivo Corporation 2020 Australia 18 years and above NA Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04334980 https://clinicaltrials.gov/show/NCT04334980 NA
10187 Spikevax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Moderna Inc. 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA NA mRNA based vaccine US FDA NA NA mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection, Elasomeran NA NCT04785144 https://clinicaltrials.gov/ct2/show/NCT04785144 NA
10188 Covax-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 1 GeneCure Biotechnologies 2020 USA 18 - 60 years 2 doses 2 weeks apart Intramuscular NA NA NA US FDA NA NA NA NA NCT04428073 https://clinicaltrials.gov/show/NCT04428073 https://delta.larvol.com/Products/bac627c1e3c7453f9c3e06990d38d930/COVAX19GC004/0/11eb4d064c904d80ad7af09be3dfc6e8/COVAX19-Monovalent-Recombinant-COVID19-Vaccine/
10189 TMV-083 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Institut Pasteur 2020 Belgium 18 - 55 years 2 doses 28 days apart Intramuscular NA Surface glycoprotein of the SARS-CoV-2 NA NA NA NA MV-SARS-CoV-2 NA NCT04497298 https://clinicaltrials.gov/show/NCT04497298 NA
10190 IN01 vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA NA Phase 1 Instituto Oncolâ—Žgico Dr Rosell 2020 Spain 18 years and above NA NA NA NA NA NA NA NA NA NA NCT04537130 https://clinicaltrials.gov/show/NCT04537130 NA
10191 V590-001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Merck & Co. Inc. 2020 USA 18 years and above NA Intramuscular NA NA NA US FDA NA NA NA NA NCT04569786 https://clinicaltrials.gov/show/NCT04569786 NA
10192 CoV2 SAM COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 GlaxoSmithKline 2021 USA 18 - 50 years 2 doses 1 month apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine NA NA NA NA NA NCT04758962 https://clinicaltrials.gov/ct2/show/study/NCT04758962 NA
10193 CORVax12 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 1 Providence Health & Services, OncoSec Medical Inc. 2021 USA 18 years and above NA Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA NA NCT04627675 https://clinicaltrials.gov/ct2/show/NCT04627675 NA
10194 ChulaCov19 mRNA vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 1 Chulalongkorn University 2021 Thailand 18 - 75 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04566276 https://clinicaltrials.gov/show/NCT04566276 NA
10239 QazCoVac-P COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Research Institute for Biological Safety Problems 2021 Kazakhstan 18 years and above 2 doses 21 days apart Intramuscular Aluminum Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04930003 https://clinicaltrials.gov/show/NCT04930003 NA
10240 RBD-HBsAg VLP COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 Serum Institute of India, Accelagen Pty 2021 Australia 18 - 79 years 2 doses 28 days apart Intramuscular CpG 1018, alum SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NA https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620001308987 NA
10241 S-268019 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Shionogi Inc. 2021 Japan 20 - 64 years NA Intramuscular NA NA NA NA NA NA NA NA NA https://jrct.niph.go.jp/en-latest-detail/jRCT2051200092 NA
10242 V-01 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Livzon Mabpharm Inc. 2021 China 18 years and above 2 doses 28 days apart Intramuscular NA Recombinant SARS-CoV-2 fusion protein NA NA NA NA NA NA NA http://www.chictr.org.cn/showproj.aspx?proj=124702 NA
10243 VLA2001 Inactivated SARS-CoV-2 vaccine (Vero cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 2 Valneva 2020 Austria 18 - 55 years 2 doses 21 days apart Intramuscular CpG 1018, aluminium hydroxide NA NA NA NA NA NA NA NCT04671017 https://clinicaltrials.gov/show/NCT04671017 NA
10244 HGCO19 (COVID-19 vaccine) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Gennova Biopharmaceuticals Limited 2020 India 18 years and above NA Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine NA HDT Biotech Corporation NA HGCO19 (COVID-19 vaccine) NA NA https://gennova.bio/mrna-vaccines/ https://vaccine.icmr.org.in/covid-19-vaccine
10245 SpikoGen COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 CinnaGen Company 2021 Iran 18 years and above 2 doses 21 days apart Intramuscular Advax-CpG Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NA http://en.irct.ir/trial/56287 NA
10246 SII B.1.617.2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Novavax Inc. 2021 Australia 18 - 64 years 2 doses 21 days apart Intramuscular Matrix-M1 Bivalent SII vaccine containing antigen for both the ancestral strain and B.1.351 (Beta) variant of SARS-CoV-2 (SII Bivalent) NA NA NA NA NA NA NCT05029856 https://clinicaltrials.gov/ct2/show/NCT05029856 NA
10247 SCB-2020S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Clover Biopharmaceuticals 2021 Australia 18 - 75 years 2 doses 22 days apart Intramuscular AS03, CpG 1018, alum SARS-CoV-2(B.1.351 variant) trimeric spike protein NA NA NA NA NA NA NCT04950751 https://www.clinicaltrials.gov/ct2/show/NCT04950751 NA
10248 EXG-5003 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Elixirgen Therapeutics Inc. 2021 Japan 20 - 55 years NA Intradermal NA NA mRNA based vaccine NA NA NA NA NA NCT04863131 https://clinicaltrials.gov/show/NCT04863131 NA
10249 BNT162a1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 BioNTech SE, Pfizer Inc. NA NA NA NA Intramuscular NA SARS-CoV-2 spike protein mRNA encapsulated in a lipid nanoparticle NA NA NA NA BNT162b1, BNT162b2, BNT162c2 32585611 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301105/ NA
10250 COVID-19 Vaccine Nasal Spray COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Xiamen University 2021 China 18 years and above 2 doses 14 days apart Intranasal NA NA NA NA University of Hong Kong, Beijing Wantai Biological Pharmacy NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10251 hAd5-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 ImmunityBio Inc. 2021 USA 18 - 80 years NA Subcutaneous NA Spike & Nucleocapsid protein NA NA NA NA NA 33937326 NCT04843722 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10252 DS-5670a COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Daiichi Sankyo Co. Ltd. 2021 Japan 20 - 74 years 2 doses Intramuscular NA NA mRNA based vaccine NA NA NA NA NA NCT04821674 https://clinicaltrials.gov/ct2/show/NCT04821674 NA
10253 ZyCoV-D COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 Cadila Healthcare Ltd NA NA NA 3 doses on day 0, 28 and 56 Intradermal NA NA NA NA NA NA nCov vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10254 GX-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 Genexine Consortium 2021 South Korea 18 - 55 years 2 doses 28 days apart Intramuscular NA SARS-CoV-2 S-protein antigen including the Nucleocapsid protein antigen NA NA NA NA NA 33816047 NCT04715997 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10255 KBP-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Kentucky Bioprocessing Inc 2021 USA 18 - 85 years 2 doses 21 days apart Intramuscular CpG 1018 SARS-CoV-2 receptor-binding domain from spike protein NA US FDA NA NA NA 33816047 NCT04473690 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10256 KD-414 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 2 KM Biologics Co. Ltd. 2021 Japan 20 years and above 2 doses 27 days apart Intramuscular NA NA NA NA NA NA NA NA NA https://jrct.niph.go.jp/en-latest-detail/jRCT2071200106 NA
10257 Vidprevtyn COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Sanofi Pasteur, GlaxoSmithKline NA NA NA 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus Baculovirus production NA NA NA VAT00002, VAT00008, SARS-CoV-2 vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10258 LUNAR-COV19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Arcturus Therapeutics 2021 Singapore NA 2 doses 28 days apart Intramuscular NA Self-replicating RNA mRNA based vaccine NA NA NA SARS-CoV-2 vaccine, ARCT-021 33816047 NCT05037097 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10259 RBD SARS-CoV-2 HBsAg VLP vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 Serum Institute of India, Accelagen Pty NA NA NA 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10260 AV-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Aivita Biomedical Inc. 2021 USA 18 years and above Single dose Intramuscular GM-CSF Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA 33816047 NCT05007496 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT05007496
10261 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 City of Hope Medical Center, National Cancer Institute 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA COH04S1 33816047 NCT04977024 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10262 hAd5-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 ImmunityBio Inc. 2021 USA 18 - 80 years Single dose Subcutaneous NA Spike & nucleocapsid protein of SARS-CoV-2 virus NA US FDA NA NA NA 33816047 NCT04843722 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10263 LV-SMENP-DC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 Shenzhen Geno-Immune Medical Institute NA NA NA Single dose Subcutaneous, Intravenous NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10264 DelNS1-2019-nCoV-RBD-OPT1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 2 Beijing Wantai Biological NA NA NA Single dose Intranasal NA NA NA NA Jiangsu Province Centers for Disease Control and Prevention NA NA 33816047 NCT04809389 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT04809389
10265 TMV-o38 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 2 Merck & Co. Inc. NA NA NA 2 doses 28 days apart Intramuscular NA NA NA NA Themis, Sharp & Dohme, Institute Pasteur, Univeristy of Pittsburgh NA V591-001—Measles-vector based 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10266 Recombinant COVID-19 Vaccine (CHO cell, NVSI-06-08) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 National Vaccine and Serum Institute 2021 China 3 years and above NA Intramuscular NA NA NA NA NA NA NA NA NCT04869592 https://clinicaltrials.gov/ct2/show/NCT05069129 NA
10267 PHH-1V COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Laboratorios HIPRA SA 2021 Spain 18 - 39 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA COVID-19 subunit vaccine NA NCT05007509 https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000074-25/ES NA
10268 COVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Vaccine and Infectious Disease Organization 2021 Canada 18 years and above 2 doses 28 days apart Intramuscular SWE Spike protein of SARS-CoV-2 virus NA NA Vaccine Formulation Institute NA NA NA NCT04702178 https://clinicaltrials.gov/ct2/show/NCT04702178 NA
10269 CoVac-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 University Hospital Tuebingen 2021 Germany 18 years and above Single dose Subcutaneous NA SARS-CoV-2 HLA-DR peptides NA NA NA NA IMP 33816047 NCT04954469 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10270 COVID-19 VLP vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 The Scientific and Technological Research Council of Turkey 2021 Turkey 18 - 59 years 2 doses 21 days apart Subcutaneous Alum adsorbed, CpG ODN Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04962893 https://clinicaltrials.gov/ct2/show/NCT04962893 NA
10271 Pasteur COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Instituto Finlay de Vacunas 2021 Cuba NA 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA FINLAY-FR-2, Pasteurcovac, Pasto Covac, Soberana 02, Soberana 2 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10272 MF59 adjuvanted SARS-CoV-2 Sclamp vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 University of Queensland 2021 Australia 18 years and above 2 doses 28 days apart Intramuscular MF59 Spike protein of SARS-CoV-2 virus NA NA NA NA SARS-CoV-2 Sclamp 33816047 NCT04495933 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10273 Comirnaty COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 BioNTech SE, Pfizer Inc. 2020 NA 18 - 55 years 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine US FDA NA NA BNT162b2, COVID-19 mRNA vaccine 33402220 NCT04368728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ https://clinicaltrials.gov/ct2/show/NCT04368728
10274 COVID-eVax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 Takis, Rottapharm Biotech 2021 Italy 18 - 65 years 2 doses 4 weeks apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04788459 https://clinicaltrials.gov/show/NCT04788459 NA
10275 ABNCoV2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 Radboud University 2021 Netherlands 18 - 55 years 2 doses 14 days apart Intramuscular MF59 NA NA NA NA NA NA NA NCT04839146 https://clinicaltrials.gov/ct2/show/NCT04839146 NA
10276 EuCorVac-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 EuBiologics Co. Ltd. 2021 South Korea 19 - 75 years 2 doses 3 weeks apart Intramuscular NA NA NA NA NA NA NA NA NCT04783311 https://clinicaltrials.gov/show/NCT04783311 NA
10277 VBI-2902a COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 2 VBI Vaccines Inc. 2021 Canada 18 years and above 2 doses 28 days apart Intramuscular Aluminum (aluminum phosphate) Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04773665 https://clinicaltrials.gov/show/NCT04773665 NA
10278 UB-612 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 United Biomedical Inc. 2021 China 12 - 85 years 2 doses Intramuscular NA NA NA NA NA NA NA NA NCT04773067 https://clinicaltrials.gov/show/NCT04773067 https://clinicaltrials.gov/ct2/show/NCT04683224
10279 COVIVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Icahn School of Medicine, Mahidol University 2021 Thailand 18 - 75 years 2 doses 28 days apart Intramuscular CpG 1018 Spike protein of SARS-CoV-2 virus NA NA NA NA ADAPTCOV, NDV-HXP-S vaccine, , HXP-GPOVac, Patria, ButanVac NA NCT04764422 https://clinicaltrials.gov/show/NCT04764422 NA
10280 AV-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 2 Aivita Biomedical Inc. 2020 USA 18 years and above NA Intranasal GM-CSF Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA NA NCT05007496 https://clinicaltrials.gov/show/NCT04386252 https://clinicaltrials.gov/ct2/show/NCT05007496
10281 AKS-452 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 University Medical Center Groningen 2021 Netherlands 18 - 65 years NA Subcutaneous NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT04681092 https://clinicaltrials.gov/show/NCT04681092 NA
10282 GLS-5310 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 GeneOne Life Science Inc. 2021 South Korea 19 - 65 years 2 doses 28 days apart Intradermal NA NA NA NA NA NA NA NA NCT04673149 https://clinicaltrials.gov/show/NCT04673149 NA
10283 MRT5500 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 2 Sanofi Pasteur, Translate Bio 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA NA mRNA based vaccine US FDA NA NA VAW00001 NA NCT04847050 https://www.clinicaltrials.gov/ct2/show/NCT04847050 NA
10284 MVA-SARS-2-ST COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 German Center for Infection Research 2021 Germany 18 years and above 2 doses 28 days apart Intramuscular NA Modified Vaccinia Virus Ankara vector expressing a stabilized SARS-CoV-2 spike protein NA NA NA NA NA NA NCT04895449 https://clinicaltrials.gov/ct2/show/NCT04895449 NA
10285 LV-SMENP COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 2 Shenzhen Geno-Immune Medical Institute 2021 China 6 months and above NA Subcutaneous NA Covid-19 minigene SMENP and immune modulatory genes NA NA NA NA NA NA NCT04276896 https://clinicaltrials.gov/show/NCT04276896 NA
10286 V-SARS COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Plasma based Phase 2 Immunitor LLC 2020 Canada 18 - 65 years NA Oral NA Pooled plasma of COVID-19 patients NA NA NA NA NA NA NCT04380532 https://clinicaltrials.gov/show/NCT04380532 NA
10287 QazVac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 2 Research Institute for Biological Safety Problems 2020 Kazakhstan 18 years and above 2 doses 21 days apart Intramuscular NA NA NA NA NA NA QazCovid-in NA NCT04530357 https://clinicaltrials.gov/show/NCT04530357 NA
10288 ZR-202-CoV COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 2 Shanghai Zerun Biotechnology, Walvax Biotechnology, CEPI 2021 China 18 years and above 2 doses 28 days apart Intramuscular CpG, alum SARS-CoV-2 protein NA NA NA NA NA NA NCT04990544 https://clinicaltrials.gov/ct2/show/NCT05313022 NA
10289 AG0302-COVID19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 2 AnGes Inc. 2021 Japan 18 years and above 3 doses 2 weeks apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04993586 https://clinicaltrials.gov/ct2/show/NCT04993586 NA
10290 AAV5-RBD-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Biocad 2021 Russia 18 - 60 years NA Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT05037188 https://clinicaltrials.gov/ct2/show/NCT05037188 NA
10291 AdCLD-CoV19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Cellid Co. Ltd. 2021 South Korea 19 - 64 years Single dose Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04666012 https://clinicaltrials.gov/ct2/show/NCT04666012 NA
10313 Convidecia COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 3 CanSino Biologics Inc. 2020 China 18 years and above Single dose Intramuscular NA NA NA NA NA NA PakVac, Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) NA NCT04526990 https://clinicaltrials.gov/show/NCT04526990 NA
10314 Nanocovax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Nanogen Pharmaceutical Biotechnology JSC 2021 Vietnam 18 years and above 2 doses 28 days apart Intramuscular Aluminum Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04922788 https://clinicaltrials.gov/show/NCT04922788 NA
10315 Omicron COVID-19 Vaccine (Vero Cell), Inactivated COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 China National Biotec Group Company Limited 2020 China NA NA Intramuscular NA NA NA NA NA NA NA NA NA http://www.chictr.org.cn/showproj.aspx?proj=62581 https://covid-19pharmacovigilance.paho.org/sinopharmbibp
10316 Inactivated SARS-CoV-2 vaccine (Vero cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Laboratorio Elea Phoenix S.A. 2020 Argentina 18 - 85 years 2 doses 21 days apart Intramuscular Aluminum (aluminium hydroxide) SARS-CoV-2 HB02 strain NA NA NA NA NA NA NCT04560881 https://clinicaltrials.gov/show/NCT04560881 NA
10317 Inactivated SARS-CoV-2 vaccine (Vero cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Health Institutes of Turkey 2020 Turkey 18 - 59 years 2 doses 14 days apart Intramuscular NA SARS-CoV-2 virus antigenic protein NA NA NA NA NA NA NCT04582344 https://clinicaltrials.gov/show/NCT04582344 NA
10318 Covidful COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Live-attenuated Phase 3 Chinese Academy of Medical Sciences 2021 China 18 years and above 2 doses 2 weeks apart Intramuscular NA NA NA NA Institute of Medical Biology Brazil, Malaysia IMBCAMS COVID-19 vaccine NA NCT04659239 https://clinicaltrials.gov/show/NCT04659239 https://clinicaltrials.gov/ct2/show/NCT05164731
10319 Recombinant SARS-CoV-2 vaccine (Sf9 Cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 West China Hospital, Sichuan University 2021 China 18 years and above 3 doses on day 0, 21 and 42 Intramuscular Aluminum (aluminium hydroxide) SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT04887207 https://clinicaltrials.gov/show/NCT04887207 https://clinicaltrials.gov/ct2/show/NCT04530656
10320 CVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 CureVac AG 2021 Belgium 18 years and above 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04860258 https://clinicaltrials.gov/ct2/show/NCT04860258?term=NCT04860258&draw=2&rank=1 NA
10321 WIBP-CorV COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Sinopharm, Wuhan Institute of Biological Products 2021 China 18 years and above 2 doses 21 days apart Intramuscular NA SARS-CoV-2 whole virus NA NA G42 Healthcare company, Abu Dhabi Health Services Company, Wuhan Institute of Biological Products Co. Ltd, Beijing Institute of Biological Products Co Ltd. China, UAE Zhongkangkewei 33816047 NCT04510207 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT04510207
10322 Convidecia COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 CanSino Biologics Inc. NA China NA Single dose Intramuscular NA NA NA NA Beijing Institute of Biotechnology NA Adenovirus type 5 vector 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10323 BNT162b1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 BioNTech SE, Pfizer Inc. NA NA NA 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NCT04368728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT04368728
10324 INO-4800 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 Inovio Pharmaceuticals 2021 USA 18 years and above 2 doses 28 days apart Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://ir.inovio.com/news-releases/news-releases-details/2021/INOVIO-Further-Expands-INNOVATE-Phase-3-Trial-for-COVID-19-DNA-Vaccine-Candidate-INO-4800-With-Regulatory-Authorization-from-India/default.aspx
10325 INO-4800 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 3 Inovio Pharmaceuticals 2021 USA 18 years and above 2 doses 28 days apart Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://www.isrctn.com/ISRCTN15779782
10326 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Novavax Inc. NA NA NA 2 doses 21 days apart Intramuscular Matrix-M1 Spike protein of SARS-CoV-2 virus NA NA NA NA TAK-019, SARS-CoV-2 rS 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10327 Covaxin COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Bharat Biotech International Limited NA India NA 2 doses 14 days apart Intramuscular NA NA NA NA NA NA BBV152 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10328 BriLife COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 Israel Institute for Biological Research 2021 Israel 18 - 55 years NA Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Weizmann Institute of Science NA IIBR-100 33937326 NCT04990466 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10329 GRAd-COV2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 ReiThera Srl 2021 Italy 18 years and above 2 doses 21 days apart Intramuscular Replication defective Simian Adenovirus (GRAd) encoding S Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33816047 NCT04791423 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10330 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 3 Janssen Vaccines & Prevention B.V. NA NA 18 years and above NA Intramuscular NA NA NA NA NA NA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10331 CVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 CureVac AG 2021 Belgium 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein mRNA based vaccine NA NA NA CVnCoV 33816047 NCT04860258 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10332 QazVac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Research Institute for Biological Safety Problems 2021 Kazakhstan 18 years and above 2 doses 28 days apart Intramuscular NA NA NA NA NA NA QazCovid-in 33816047 NCT04691908 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10333 AG0301-COVID19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 3 AnGes Inc. 2021 Japan 18 years and above 2 doses 14 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Japan Agency for Medical Research and Development NA NA 33816047 NCT04655625 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10334 AWcorna COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 Academy of Military Sciences, Walvax Biotechnology Co. Ltd. 2021 China 18 years and above 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine NA NA NA Walvax COVID-19 vaccine, ARCoV NA NCT04847102 https://delta.larvol.com/products/?ProductId=4355caae-8746-469c-ab52-0b40ddfde811&Index=0 NA
10335 ARCT-154 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 Vinbiocare Biotechnology Joint Stock Company 2021 Vietnam 18 years and above 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Arcturus Therapeutics Inc. NA VBC-COV19-154 NA NCT05012943 https://clinicaltrials.gov/ct2/show/NCT05012943 NA
10336 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 AstraZeneca plc 2021 Brazil 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 variant strain B.1.351 NA NA NA Brazil, UK, South Africa AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NCT04973449 https://clinicaltrials.gov/ct2/show/NCT04973449 NA
10337 SCB-2019 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Clover Biopharmaceuticals 2021 Australia 18 years and above 2 doses 21 days apart Intramuscular AS03, CpG 1018, alum Spike protein of SARS-CoV-2 virus NA NA GlaxoSmithKline, Dynavax NA NA 33816047 NCT04672395 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10338 Covifenz COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 3 Medicago Inc NA NA NA 2 doses 21 days apart Intramuscular NA NA NA NA NA NA CoVLP 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10339 UB-612 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Vaxxinity 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10340 Recombinant SARS-CoV-2 vaccine (Sf9 Cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 West China Hospital, Sichuan University 2021 China 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10341 AZD1222 (ChAdOx1) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 3 Janssen Pharmaceutical NA NA 18 - 55 years 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33402220 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ NA
10342 WIBP-CorV COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Wuhan Institute of Biological Products NA NA 18 - 59 years Single dose Intramuscular NA Inactivated SARS-CoV-2 virus NA NA NA NA NVX-CoV2373 33402220 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ NA
10343 Vidprevtyn COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Sanofi Pasteur, GlaxoSmithKline 2021 USA 18 years and above 2 doses 14 days apart Intramuscular NA SARS-CoV-2 protein NA NA GlaxoSmithKline USA, Colombia, Honduras, Japan, Kenya VAT00002, VAT00008 NA NCT04904549 https://clinicaltrials.gov/ct2/show/NCT04904549 https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-3-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate
10344 CVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 CureVac AG NA Germany NA NA Intramuscular NA NA mRNA based vaccine NA NA Germany, Cuba, Peru CVnCoV NA NCT04674189 https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://clinicaltrials.gov/ct2/show/NCT04674189
10345 CoV2 preS dTM-AS03 vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Sanofi Pasteur NA NA NA NA Intramuscular NA NA Recombinant EMA NA NA NA NA NCT04904549 https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://clinicaltrials.gov/ct2/show/NCT04762680
10346 SCB-2019 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Clover Biopharmaceuticals NA Australia NA NA Intramuscular NA NA Novel recombinant SARSCoV-2 Spike trimer fusion protein NA NA Belgium, Brazil, Colombia, Dominican Republic, Germany, Nepal, Panama, Philippines, Poland NA NA NCT04405908 https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://clinicaltrials.gov/ct2/show/NCT04405908
10347 COVIran Barekat COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Shifa Pharmed Industrial Co. 2021 Iran 18 - 75 years 2 doses 28 days apart Intramuscular NA NA NA NA NA NA BIV1-CovIran, COVIran Barkat NA NA http://en.irct.ir/trial/54881 https://en.irct.ir/trial/52701
10348 GRAd-COV2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 3 ReiThera Srl NA Italy 18 years and above 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04791423 https://clinicaltrials.gov/show/NCT04791423 NA
10349 Vidprevtyn COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Sanofi Pasteur 2021 USA 18 years and above 2 doses 21 days apart Intramuscular AS03 SARS-CoV-2 protein NA US FDA GlaxoSmithKline NA VAT00002, VAT00008 NA NCT04762680 https://clinicaltrials.gov/show/NCT04762680 https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-3-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate
10350 Skycovion COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 SK Bioscience Co. Ltd. 2021 South Korea 19 - 85 years 2 doses 28 days apart Intramuscular AS03 Recombinant SARS-CoV-2 protein NA NA International Vaccine Institute, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations NA GBP510 NA NCT04750343 https://clinicaltrials.gov/show/NCT04750343 NA
10351 QazVac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Research Institute for Biological Safety Problems 2020 Kazakhstan 18 years and above 2 doses 21 days apart Intramuscular NA NA NA NA NA NA QazCovid-in NA NCT04691908 https://clinicaltrials.gov/show/NCT04691908 NA
10352 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Novavax Inc. 2020 Australia 18 - 59 years 2 doses 21 days apart Intramuscular NA NA NA US FDA NA NA TAK-019, SARS-CoV-2 rS NA NCT04368988 https://clinicaltrials.gov/show/NCT04368988 https://clinicaltrials.gov/ct2/show/NCT04368988
10353 COVIVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Instituto Butantan 2020 Brazil 18 years and above 2 doses 2 weeks apart Intramuscular NA NA NA NA NA NA ADAPTCOV, NDV-HXP-S vaccine, , HXP-GPOVac, Patria, ButanVac NA NCT04456595 https://clinicaltrials.gov/show/NCT04456595 NA
10354 SCTV01C COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Subunit vaccine Phase 3 Sinocelltech Ltd. 2021 China 18 years and above 2 doses 14 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT05043311 http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5890 NA
10355 CoviVac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Chumakov Centre at the Russian Academy of Sciences 2021 Russia 18 - 60 years 2 doses 14 days apart Intramuscular NA Inactivated SARS-CoV-2 virus NA NA NA NA NA NA NA https://www.precisionvaccinations.com/vaccines/covivac-russia-covid-19-vaccine NA
10375 OMB157 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 4 Novartis 2021 Germany 18 years and above NA Subcutaneous NA NA NA NA NA NA Ofatumumab NA NCT04869358 https://clinicaltrials.gov/show/NCT04869358 https://www.ema.europa.eu/en/documents/assessment-report/kesimpta-epar-public-assessment-report_en.pdf
10376 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 4 AstraZeneca plc, University of Oxford, Serum Institute of India 2020 UK 18 years and above 2 doses 4 to 12 weeks apart Intramuscular NA Spike protein of SARS-CoV-2 virus ChAdOx1 technology NA University of Oxford Japan, Korea, India AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://vk.ovg.ox.ac.uk/vk/covid-19-vaccines NA